Introduction to TLS in Lung Cancer

Tertiary lymphoid structures (TLS) represent organized immune cell aggregates that form within the tumor microenvironment. These structures essentially act as local hubs for antitumor immune responses. Recent evidence suggests that their presence is often associated with improved survival in various malignancies. However, identifying the specific molecular drivers that regulate their maturation remains a challenge for clinicians. A recent study has now shed light on how DKK1 expression NSCLC influences these structures and overall patient prognosis.

The Role of the TLS Risk Score (TLSRS)

Researchers utilized consensus clustering and LASSO-Cox regression to develop a TLS-related risk score, termed TLSRS. This scoring system effectively categorized patients into high- and low-risk groups across multiple cohorts. Notably, patients in the low-risk group exhibited significantly better survival outcomes. In contrast, those with high risk scores showed a suppressed immune profile. This findings suggest that molecular signatures related to TLS can serve as potent biomarkers for risk stratification in clinical settings.

Impact of DKK1 Expression on NSCLC Prognosis

The study specifically highlighted Dickkopf-1 (DKK1) as a central gene within the TLSRS. Clinical analysis using multiplex immunofluorescence revealed a striking negative correlation between DKK1 expression NSCLC and the maturity of tertiary lymphoid structures. Higher levels of DKK1 were consistently found in tumors with immature or absent TLS. Consequently, these patients faced a poorer prognosis. Furthermore, the researchers observed that DKK1 might actively inhibit the transition of TLS from early aggregates to mature, functional follicles containing germinal centers.

Clinical Implications for Immunotherapy

Understanding the interplay between DKK1 and TLS maturity provides new avenues for personalized medicine. Because mature TLS are associated with better responses to immune checkpoint inhibitors, DKK1 could potentially serve as a predictive marker for immunotherapy efficacy. Future therapeutic strategies might focus on targeting DKK1 to promote TLS maturation, thereby enhancing the body's natural antitumor defenses. This approach could be particularly beneficial for patients currently classified in the high-risk TLSRS category.

Frequently Asked Questions

What are tertiary lymphoid structures (TLS)?

TLS are organized clusters of immune cells, including B cells and T cells, that form directly within or near tumor tissues. They resemble secondary lymphoid organs like lymph nodes and help coordinate local immune attacks against cancer cells.

How does DKK1 expression affect TLS maturity?

High DKK1 expression is associated with a lack of mature TLS. It appears to interfere with the structural organization of these immune aggregates, preventing them from developing into mature follicles that are necessary for a robust immune response.

Why is the TLSRS score important for clinicians?

The TLSRS score provides a molecular tool to predict patient survival more accurately than traditional staging alone. It helps identify high-risk patients who may require more aggressive or specialized treatment interventions.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare guidance. Always seek the advice of a qualified physician or other health provider regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Ma L et al. DKK1 expression associates with tertiary lymphoid structure maturity in non-small cell lung cancer. Apoptosis. 2026 Mar 29. doi: undefined. PMID: 41904774.

Silina K et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Associated with Increased Survival in NSCLC. Frontiers in Immunology. 2018;9:1909.

Geng Y et al. Dickkopf-1 (DKK1) promotes tumor growth and metastasis in non-small cell lung cancer. International Journal of Oncology. 2024.